New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib

Baricitinib is an innovative small-molecule drug that reversibly inhibits continuous activation of JAK/STAT pathway, thus reducing joint inflammation. The drug was approved for use as monotherapy or in combination with methotrexate (MTX) in the treatment of adults with moderately to severely active...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawalec, Paweł, Śladowska, Katarzyna, Malinowska-Lipień, Iwona, Brzostek, Tomasz, Kózka, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385775/
https://www.ncbi.nlm.nih.gov/pubmed/30858707
http://dx.doi.org/10.2147/TCRM.S192440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385775/
https://www.ncbi.nlm.nih.gov/pubmed/30858707
http://dx.doi.org/10.2147/TCRM.S192440

Ejemplares similares